title: Comparative absorption of bismuth in Sprague-Dawley rats following oral administration of preparations containing bismuth sucrose octasulfate, bismuth subsalicylate, and bismuth subcitrate.
abstract: The absorption of bismuth from De-Nol (bismuth subcitrate, DN), Pepto-Bismol (bismuth subsalicylate, PB) and bismuth sucrose octasulfate (BISOS) was examined in male Sprague-Dawley rats after a single oral dose of each compound (60mg bismuth). Bismuth was analysed in blood, urine, kidney, brain, liver, and lung using graphite furnace atomic absorption spectrophotometry. Bismuth Cmax averaged 18.4 +/- 11.6 ng mL(-1) for BISOS, 292 +/- 130 ng mL(-1) for DN, and 21.5 +/- 9.63 ng mL(-1 ) for PB. Cmax was significantly lower for BISOS compared to DN (p<0.05) but not significantly different for BISOS compared to PB (p > 0.05). Bismuth AUC was 1356 +/- 474 ng h(-1) mL (-1) for BISOS, 2129 +/- 452 ng h(-l) mL(-1) for DN, and 1824 +/- 919 ng h(-1) for PB, which indicated a lower extent of absorption from BISOS compared to DN. Kidney, liver, and lung levels of bismuth were also significantly lower for BISOS compared to DN (p < 0.05). Bismuth urinary excretion was significantly lower for BISOS (0.04 +/- 0.02%) compared to DN (0.27 +/- 0.15%) but not significantly different compared to PB (0.07 +/- 0.03%). These data suggest that the absorption of bismuth following oral administration of bismuth sucrose octasulfate is significantly lower than that from De-Nol and similar to that from Pepto-Bismo.
authors.affiliation: Department of Clinical Pharmacokinetics, Hoechst Marion Roussel, Kansas City, MO 64137, USA. NiranjanRao@HMRI.COM
authors.forename: N
authors.initials: N
authors.lastname: Rao
authors.forename: P W
authors.initials: PW
authors.lastname: Brown
authors.forename: P
authors.initials: P
authors.lastname: Yerino
authors.forename: J
authors.initials: J
authors.lastname: Chang
authors.forename: K K
authors.initials: KK
authors.lastname: Hwang
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000863:Antacids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001729:Bismuth / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007408:Intestinal Absorption; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012459:Salicylates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013054:Spectrophotometry, Atomic; D013395:Sucrose / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D000863:Antacids; D009942:Organometallic Compounds; D012459:Salicylates; D013395:Sucrose; C015715:bismuth subsalicylate; C002791:bismuth tripotassium dicitrate; C053081:sucrose octasulfate; D001729:Bismuth